{'fraction_non_alphanumeric': 0.01900739176346357, 'fraction_numerical': 0.0021119324181626186, 'mean_word_length': 4.962264150943396, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Generic substitutions of antiepileptic drugs: Is it possible to put an end to the discussion?

A policy on generic substitutions, which is aimed at reducing the cost-effectiveness of pharmacotherapy, was proposed by the WHO at the end of the 20th century; however, but the debate about their  economic benefits has continued until now. There have been the  most active discussions of whether an epileptic patient may be  switched from brand-name to generic antiepileptic drugs. The paper  gives data obtained in Russian and foreign studies of the therapeutic  efficacy and safety of anticonvulsant generics versus their brand- name drugs, as well as the impact of generic substitutions on the cost-effectiveness of  antiepileptic therapy. Emphasis is placed on the importance of the  quality of generic medicines, their dosage forms, and regulatory requirements for registration of generics. The problem of generic instability is under discussion.